NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), announced today the presentation of ZIO-101 (darinaparsin) Phase I/II advanced multiple myeloma data at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The poster entitled, “ZIO-101 (S-dimethylarsino-glutathione): Phase 1/2 trials in advanced / progressive multiple myeloma” was presented by J.R. Berenson, M.D., Berenson Oncology, Inc., West Hollywood, CA, and principal investigator. Darinaparsin is a novel organic arsenic with a multifaceted mechanism of action different from other forms of arsenic commercially available.
